NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Harrison, SA; Abdelmalek, MF; Trotter, JF; Paredes, AH; Arnold, HL; Kugelmas, M; Bashir, MR; Ling, L; Rossi, SJ; DePaoli, AM; Rinella, ME; Loomba, RS

Published Date

  • 2017

Published In

Volume / Issue

  • 66 / 1

Start / End Page

  • S92 - S93

Published By

International Standard Serial Number (ISSN)

  • 0168-8278

Digital Object Identifier (DOI)

  • 10.1016/s0168-8278(17)30448-8